Application Serial No.: 10/796,882 Response dated September 25, 2007

Amendments to Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1-16, (Cancelled)

17. (Currently Amended) An extracorporeal blood eireuit for filtration circuit for treating ef-a patient's blood to remove target molecules and target complex molecules, the circuit comprising: the blood circuit a line adapted operable to remove and to return a portion of the patient's blood:

a blood filter operably coupled with the blood circuit line so as to allow the portion of the patients' blood to flow therethrough[[:]] she blood filter-and the circuit-operable to form a stream of filtered blood and a stream of an ultrafiltrate; the blood filter and other portions of the blood circuit operable to remove the ultrafiltrate from the portion of the patient's blood with ultrafiltration rates of between-approximately two liters per hour and twenty liters per hour[[:]], the blood filter having a nominal molecular weight cutoff of greater than 150,000 Daltons so as to sieve more than a nominal amount of the target molecules and the target complex molecules from the portion of the patient's blood; the molecular weight cutoff of the blood filter selected and to avoid removal of-significant amounts of immunoelobulins from the portion of the patients' blood:

a source for infusing a replacement fluid into the blood circuit, the source including replacement fluid comprising having clean target receptor molecules[[,]] in sufficient amount so as into the blood circuit to provide sufficient clean target receptor molecules to attract sequester inflammatory mediators and toxins from the patient's tissue and to spaces and tissue binding sites in the patient; the clean target receptor molecules in the replacement fluid replacing replace the target receptor molecules sieved from the portion of the patient's blood by the blood filter, and the replacement fluid comprising a pharmaceutical grade balanced salt solution with sufficient clean albumin to maintain adequate plasma oncotic pressure with ultrafiltration rates between approximately two liters per hour and twenty liters per hour in a sufficient concentration to adequately replenish ongoing losses.

18. (previously presented) The extracorporeal blood circuit of Claim 17 wherein the replacement fluid comprises a concentration of albumin in the fluid greater than approximately 0.5 grams per one hundred milliliters.

- 19. (previously presented)) The extracorporeal blood circuit of Claim 17 wherein the replacement fluid comprises a concentration of albumin in the fluid less than approximately twenty grams per one hundred milliliters.
- 20. (previously presented) The extracorporeal blood circuit of Claim 17 wherein the blood filter comprises a nominal molecular weight cut off less than 5,000,000 Daltons.
- 21. (previously presented) The extracorporeal blood circuit of Claim 17 wherein the blood filter comprises a nominal molecular weight cut off less than 1,000,000 Daltons.
- 22. (previously presented) The extracorporeal blood circuit of Claim 17 wherein the blood filter comprises a nominal molecular weight cut off less than 500,000 Daltons.
- 23 (new) The extracorporeal blood circuit of Claim 17, wherein the clean target receptor molecules are albumin molecules
- 24. (new) A method for removing toxic substances from the blood of a patient, the method comprising:

withdrawing blood from the patient;

delivering the blood to a hemofilter having a molecular weight cutoff of greater than 150,000 Daltons and less than 1,000,000 Daltons so as to create a return stream and an ultrafiltrate:

removing at least a portion of the ultrafiltrate;

returning the return stream to the patient; and

providing a fluid, containing clean target receptor molecules, to the patient.

- 25. (new) A method according to claim 24 wherein the molecular weight cutoff is a nominal molecular weight cutoff.
- 26. (new) A method according to claim 24 wherein the target receptor molecules comprise albumin.
- 27. (new) A method according to claim 24 wherein the target receptor molecules consist of albumin.

Application Serial No.: 10/796,882 Response dated September 25, 2007

- 28. (new) A method according to claim 24 wherein the target receptor molecules consist of albumin and another substance.
- 29. (new) A method according to claim 28 wherein the other substance is a specific target receptor.
- 30. (new) A method according to claim 24 wherein providing the fluid includes delivering albumin sufficient to maintain adequate oncotic pressure.
- 31. (new) A method according to claim 24 further comprising removing all of the ultrafiltrate,
- 32. (new) A method according to claim 24 further comprising cleaning and returning at least a portion of the ultrafiltrate.
- 33 (new) A method according to claim 32 wherein cleaning includes using an adsorbent material.
- 34 (new) A method according to claim 24, wherein removing includes removing a predetermined amount of ultrafiltrate based on one of the body size of the patient, the time of therapy, and the rate of flow of blood to the hemofilter.
- 35 (new) A method according to claim 24 wherein removing includes adjusting the rate of ultrafiltrate removal by altering the rate of delivering blood to the hemofilter.
- 36 (new) A method according to claim 24 wherein providing the fluid includes delivering the fluid to the patient via a line.
- 37 (new) A method according to claim 36 wherein providing the fluid includes providing it concurrently with removing at least a portion of the ultrafiltrate.
- 38. (new) A method according to claim 24 wherein the toxic substances are pro-inflammatory mediators.
- 39. (new) A method according to claim 38 further comprising practicing the withdrawing, delivering, removing, returning and providing so as to remove a sufficient amount of inflammatory mediators so

Application Serial No.: 10/796,882 Response dated September 25, 2007

as to effect an anti-inflammatory response from the patient.

- 40. (new) A method according to claim 24, further comprising infusing the fluid directly into the patient.
- 41. (new) A method according to claim 24, further comprising infusing the fluid into a blood circuit associated with the hemofilter.
- 42. (new) A method according to claim 24, further comprising practicing the withdrawing, delivering, removing, returning and providing over a duration of between 4-24 hours.
- 43. (new) A method according to claim 24, further comprising using an ultrafiltration rate of between 2 and 20 liters per hour.
- 44. (new) A method according to claim 46, further comprising using an ultrafiltration rate of between 6 and 12 liters per hour.